Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Clonidine · Kapvay, ST-155-BS

Small molecule · Agonist of alpha-2 adrenergic receptor (ADRA2A) · developed by Concordia Pharms

Approved FDA, Sep 2009
1 Registered trials

What is Clonidine?

Clonidine is an imidazoline derivative that binds to and stimulates central alpha-2 adrenergic receptors, reducing norepinephrine release and sympathetic outflow to the heart, kidneys and peripheral vasculature. It also binds imidazoline receptor subtype 1 (I1), which may contribute to its blood-pressure-lowering effect. It is studied in pregnancy-related conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kapvay, ST-155-BS
Drug type
Small molecule
Targets
alpha-2 adrenergic receptor (ADRA2A), imidazoline receptor subtype 1 (I1) (secondary target)
Mechanism
Agonist of alpha-2 adrenergic receptor (ADRA2A)
Pathways
sympathetic outflow reduction, norepinephrine release reduction
Therapy area
Cardiovascular
Developer
Concordia Pharms Inc
In trials of
GRCE
FDA status
Approved as Kapvay (September 29, 2009), NDA022331
UNII
MN3L5RMN02

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05487196 Phase 2 Pregnancy Related Completed GRCE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pregnancy Related

Other drugs acting on ADRA2A

Brimonidine FDA approved BXCL501 FDA approved Dexmedetomidine FDA approved BTOS-HA Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.